Loading
A phase 1/2 trial of EB-DART-NK01 in small-cell lung cancer, run by Beijing Biotech, now recruiting.
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) is a phase 1/2 interventional study registered as NCT07744256 by Beijing Biotech, with 60 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-02-14. Interventions recorded: EB-DART-NK01 and Lymphodepleting chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GD2 (disialoganglioside), DLL3, Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares DLL3 and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/